The New York Entrepreneur

: Drugmakers’ deal making will plow ahead despite antitrust scrutiny, analysts say

Read Time:5 Second

Big pharma goes shopping as “patent cliff” puts more than $225 billion in revenues at risk.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post : Inflation is cooling, but that does not mean cheaper trips to the grocery store
Next post : Cirrus Logic to cut 5% of global workforce